- Total revenues rose 4% year-over-year to $832.5M, driven by Tyvaso DPI (+13%).
- Net income declined 24% to $258.6M; diluted EPS fell 20% to $5.71 from $7.16 in Q3 2025.
- Nebulized Tyvaso sales dropped 12% and Remodulin fell 3%.
Why is $UTHR moving today? · SEC 8-K archive
$UTHR SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $UTHR: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $UTHR filing catalyst
Why did $UTHR trigger an AI stock catalyst alert?
$UTHR triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -4.5/10). Headline: United Therapeutics Reports Q3: Net Income Drops 24% Despite 4% Revenue Rise. Key points: - Total revenues rose 4% year-over-year to $832.5M, driven by Tyvaso DPI (+13%). - Net income declined 24% to $258.6M; diluted EPS fell 20% to $5.71 from $7.16 in Q3 2025. - Nebulized Tyvaso sales dropped 12% and Remodulin fell 3%.
How did $UTHR stock react after the SEC filing?
After the SEC 8-K for $UTHR, observed market reaction: T0 price $601.32. Past moves do not guarantee future results.
Where can I get real-time $UTHR SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $UTHR via Telegram and the VIP Web Terminal from €10/month.